Format

Send to

Choose Destination
Clin Lab Med. 2016 Sep;36(3):557-73. doi: 10.1016/j.cll.2016.05.003.

The Future of Precision Medicine in Oncology.

Author information

1
PGXL Technologies, 201 East Jefferson Street, Suite 306, Louisville, KY 40202, USA; Department of Pathology and Laboratory Medicine, University of Louisville, Louisville, KY, USA.
2
PGXL Technologies, 201 East Jefferson Street, Suite 306, Louisville, KY 40202, USA; Department of Engineering, University of Louisville, Louisville, Kentucky, USA. Electronic address: lindsay.strotman@pgxlab.com.

Abstract

Precision medicine in oncology focuses on identifying which therapies are most effective for each patient based on genetic characterization of the cancer. Traditional chemotherapy is cytotoxic and destroys all cells that are rapidly dividing. The foundation of precision medicine is targeted therapies and selecting patients who will benefit most from these therapies. One of the newest aspects of precision medicine is liquid biopsy. A liquid biopsy includes analysis of circulating tumor cells, cell-free nucleic acid, or exosomes obtained from a peripheral blood draw. These can be studied individually or in combination and collected serially, providing real-time information as a patient's cancer changes.

KEYWORDS:

Cell-free nucleic acid (cfNA); Circulating tumor cell (CTC); Exosomes; Extracellular vesicle (EV); Liquid biopsy; Targeted therapy

PMID:
27514468
DOI:
10.1016/j.cll.2016.05.003
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center